InVivo Therapeutics’ CEO Frank Reynolds Scheduled to Appear on WCVB-TV in Boston Toni

[manouli]

I must say that he is an excellent promoter.


InVivo Therapeutics’ CEO Frank Reynolds Scheduled to Appear on WCVB-TV in Boston Tonight
Press Release: InVivo Therapeutics Holdings Corp. – 3 hours ago




CAMBRIDGE, Mass.--(BUSINESS WIRE)--

InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and neurotrauma conditions, today announced that CEO Frank Reynolds is scheduled to appear on WCVB-TV in Boston tonight, August 21st during the 11:00pm EDT newscast.



more...

http://finance.yahoo.com/news/invivo...203900884.html

[manouli]

today's news is that they will start trials with animals, I thought they will start with people.




Wednesday, August 22, 2012

InVivo Therapeutics scientist gets $10K grant
By Don Seiffert




A neurosurgeon at InVivo Therapeutics Holdings Corp. has been given a $10,000 MDH Research Award for a project to reduce scarring of the spinal cord following surgery using a drug-releasing, injectable biomaterial.

According to a statement, Amer Khalil got the grant from MDHonors, a division of LeadPhysician, an international physician organization based in London with more than 500,000 members.

Khalil told Mass High Tech that the company has been working for at least four years on a biomaterial - consisting of a polymer containing drugs, stem cells and other biological agents - which can be injected into the spinal cord to minimize scarring and encourage regeneration. Khalil plans to begin animal studies next month, which should last for a year, to determine the right combination of agents to include in the polymer. He said that down the road, the technology has applications beyond spinal cord scarring, such as in the field of plastic surgery.

read...

http://www.masshightech.com/stories/...10K-grant.html

[manouli]

Rodman and Renshaw Annual Healthcare Conference09/06/2012 | 06:05am US/Eastern

InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and neurotrauma conditions, today announced that CEO Frank Reynolds is scheduled to present to investors at the 2012 14th Annual Rodman and Renshaw Healthcare Conference to be held September 9-11, 2012 at the Waldorf Astoria in New York City. InVivo's presentation will be on Tuesday, September 11th at 10:00 a.m. EDT in the Starlight Center room. A live webcast will be available at http://www.wsw.com/webcast/rrshq22/nviv.

read...

http://www.4-traders.com/INVIVO-THER...ealt-14491830/

[manouli]

September 11, 2012 06:00 AM Eastern Daylight Time
InVivo Therapeutics Announces Business Updates
Rodman & Renshaw Global Investment Conference 2012


CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and neurotrauma, today announced several business updates. The highlights are being provided in connection with the Company’s presentation today at the 14th Annual Rodman and Renshaw Healthcare Conference at the Waldorf Astoria in New York City.

Highlights include:

Human clinical trial for “First in Man” use of biopolymer scaffolding to treat acute SCI expected to commence in early 2013 under a Humanitarian Device Exemption (HDE) pathway, pending FDA approval of the related IDE application.
The Company expects that the FDA will require five patients for the pilot study and that the product will be regulated under a Humanitarian Device Exemption pathway, both factors that InVivo believes will accelerate product commercialization.
InVivo’s 2011 non-human primate study confirms the treatment effect of the scaffold devices seen in the 2008 and 2009 non-human primate studies.
Strong financial position: InVivo raised $20 million in early 2012 from a select group of institutional investors and had $18.0 million of cash on hand at June 30, 2012, sufficient to fund operations into 2014. Exercise of warrants has potential to raise an additional $16.7 million of cash.
more...

http://www.businesswire.com/portal/s...46&newsLang=en

[ineedmyelin]

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. (More...)

Not including CEO Frank Reynolds continuing his TV tour (what is this accomplishing, again?) there have been precious few updates lately from Invivo Therapeutics (NVIV.OB). It's been more than a year since Invivo filed for a phase I clinical trial with the FDA and they are still awaiting permission:

The Company has submitted an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) for a proprietary biopolymer scaffolding device to protect and support spinal tissue and prevent secondary injury, including inflammation and glial scarring, following traumatic spinal cord injury. The Company has requested permission to initiate an open-label study of 10 patients with acute spinal cord injuries within several days of injury.

If they are granted such rights, the guesstimates have them beginning human trials at the beginning of next year, but that is entirely up to the FDA.

Last year Invivo partnered with the Miami Project, a University of Miami program with the laudable mission of curing paralysis:

The collaboration will evaluate InVivo's biopolymer devices synergistically combined with cellular therapies, including The Miami Project's Schwann cell technologies. Key components of the research collaboration agreement include:

-- in vitro and in vivo studies with combinations of biomaterials, Schwann cells and other cellular therapies and drugs

-- joint ownership of resulting intellectual property

-- right of first offer for InVivo to license and commercialize on a worldwide exclusive basis

There has been some good news lately for the Miami Project:

The Miami Project to Cure Paralysis, a Center of Excellence at the University of Miami Miller School of Medicine, has received permission from the Food and Drug Administration to begin a revolutionary Phase 1 clinical trial to evaluate the safety of transplanting human Schwann cells to treat patients with recent spinal cord injuries.

Found mainly in the peripheral nervous system, Schwann cells are essential to sending appropriate electrical signals through the nervous system, and Miami Project scientists and supporters believe they are key to finding cures for paralysis. In what will be the only FDA-approved cell therapy-based clinical trial for sub-acute spinal cord injury in the United States, investigators plan to transplant a patient's own Schwann cells at the injury site in the hope of ascertaining safety that will allow further trials to proceed.

This is good news, they are allowed to conduct some studies to see if further studies will be safe. Good. The "revolutionary" part seems like a bit much to describe a very early stage trial. But then you read this part:

"We believe today's announcement is just as important to our field as man's first step on the moon was to the space program," said neurosurgeon Barth Green, M.D., Co-Founder and Chairman of The Miami Project."

Funny how CNN missed this giant leap for mankind.

Permission to do a Phase I trial = walking on the moon. Hmmm. Misters Armstrong and Aldrin might take exception to that. Any objective observer might take exception to that.

So the only news out of the Invivo camp is that the CEO continues to promote his stock on a national television tour, just like ... well, like no other CEO. That and their partner had a nice incremental step toward their stated goal, which they promptly compared to the greatest feat in human history.

Compare the promoting Invivo does to companies Google lists as similar like Edwards Lifesciences Corp. (EW), MELA Sciences (MELA), Accuray Incorporated (ARAY), BioDelivery Sciences International (BDSI), Coronado Biosciences (CNDO). No other company is pumping their stock this way.

Two questions for Invivo CEO Frank Reynolds:

1) If Invivo's prospects are as good as you say they are on your unprecedented media tour, why then are you dumping your own shares?

Mr. Reynolds promotes his company in an unprecedented manner, he is all over the airwaves. Does he believe the story? Is he holding on to his shares or even picking some up? Nope. Already this year Mr. Reynolds has sold nearly 1 million shares, and all reported insider transactions have been to get out:


(Click to enlarge)

Compare that to another speculative stock I think is a terrific buy right here, MannKind (MNKD):


(Click to enlarge)

Both CEOs are telling everyone who will listen that their company is on the verge of greatness. But as they are saying that one CEO is dumping millions of dollars worth of shares while the other is accumulating tens of millions of dollars worth. Is it reasonable to doubt that Dr. Mann believes in his company? Is it reasonable to believe that Mr. Reynolds has this same conviction?

2) If the scientific claims that your company has made can stand up to scrutiny, and the company's finances are fair to shareholders, why on Earth is your company not on a major exchange like the NASDAQ?

Most investors never even consider buying an over the counter stock. Indeed, on average a stock's volume more than doubles after it lists on a major exchange. Can there be any doubt uplisting would bring in buyers and meaningfully increase the share price?

The transparency, regulatory oversight, corporate governance, and financial filing requirements of being on a major exchange give investors peace of mind. The company they are getting a piece of is likely on the up and up. Things like warrants and capital structure are not left to the imagination and we can see just what executives are doing with shareholder money.

Mr. Reynolds company has questions that would be answered by the vetting process and on-going requirements of uplisting to the NASDAQ. Why don't they do it?

The most reasonable answer is that they do not want the scrutiny. Firms would not like what they saw if they got to do real diligence on the finances and/or science of this company. Full stop. Sell Invivo.

http://seekingalpha.com/article/8268...dumping-shares

[Chaz19]

The job of a CEO is to promote his business- can't fault him for that.

[manouli]

InVivo Therapeutics Opens New Office and Labs in Cambridge, Massachusetts

CAMBRIDGE, Mass. -- (BUSINESS WIRE) -- InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and Neurotrauma, today hosted a ribbon cutting ceremony for the company’s new office, manufacturing and lab space at One Kendall Square, Building 1400 in Cambridge, Massachusetts. Consolidating all of InVivo’s operations, the 21,000 square foot facility will serve as the new headquarters for the company.

Speakers at the event included InVivo Therapeutics co-founder and CEO Frank Reynolds; Massachusetts Life Sciences Center President & CEO Susan Windham-Bannister, PhD; MassBio Director of Economic Development & Global Affairs Peter Abair; and Mike Ferriter, a founder and Board member of the Greater Boston Chapter of the National Spinal Cord Injury Association. InVivo Therapeutics received $500,000 in early-stage loan financing through the Massachusetts Life Sciences Center’s Accelerator Program in 2009 when the company had six employees. The company has since raised $35 million in public financing and has grown to over thirty employees. The Life Sciences Center is the agency charged with implementing the state’s ten-year, $1 billion Life Sciences Initiative.

more...

http://www.freshnews.com/news/704696...-massachusetts

[GRAMMY]

http://www.massdevice.com/news/inviv...ersonnel-moves

Ed Wirth, CSO has resigned from InVivo.

[Fly_Pelican_Fly]

Interesting development!

[c473s]

Originally Posted by GRAMMY

http://www.massdevice.com/news/inviv...ersonnel-moves

Ed Wirth, CSO has resigned from InVivo.

He had brought some much needed credibility among the researcher world. Ed told several people in London a few weeks ago he was leaving to do consulting.